Location of EGFR exon 20 insertions matters.

[1]  J. Heymach,et al.  Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. , 2022, Cancer cell.

[2]  F. Klauschen,et al.  Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Jing Wang,et al.  Structure-based classification predicts drug response in EGFR-mutant NSCLC , 2021, Nature.

[4]  R. Rosell,et al.  Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities , 2021, British Journal of Cancer.

[5]  E. Dmitrovsky,et al.  A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components , 2020, Science Translational Medicine.

[6]  J. Minna,et al.  EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer , 2020, Nature Cancer.

[7]  R. Rosell,et al.  EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). , 2018, Lung cancer.

[8]  J. Minna,et al.  TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer , 2018, The Journal of clinical investigation.

[9]  K. Politi,et al.  Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.

[10]  G. Girolomoni,et al.  ERK1/2 Regulates Epidermal Chemokine Expression and Skin Inflammation1 , 2005, The Journal of Immunology.

[11]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.